HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

ridogrel

structure given in first source; has thromboxane A2 synthetase inhibition & thromboxane A2/prostaglandin endoperoxide receptor blocking activity
Also Known As:
5-((((3-pyridinyl)(3-(trifluoromethyl)phenyl)methylene)amino)oxy)pentanoic acid; R 68,070; R 68070; R 70416; R-68070; R-70416; Pentanoic acid, 5-(((3-pyridinyl(3-(trifluoromethyl)phenyl)methylene)amino)oxy)-, (E)-
Networked: 29 relevant articles (7 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Carty, E: 3 articles (05/2002 - 06/2000)
2. Rampton, D S: 3 articles (05/2002 - 06/2000)
3. Lebel, Marcel: 2 articles (08/2004 - 03/2003)
4. Moreau, Claudia: 2 articles (08/2004 - 03/2003)
5. Larivière, Richard: 2 articles (08/2004 - 03/2003)
6. Rodrigue, Marie-Eve: 2 articles (08/2004 - 03/2003)
7. Lawrance, Ian Craig: 1 article (10/2010)
8. Kulp, Werner: 1 article (01/2006)
9. Greiner, Wolfgang: 1 article (01/2006)
10. Gorenoi, Vitali: 1 article (01/2006)

Related Diseases

1. Ulcerative Colitis
2. Thrombosis (Thrombus)
08/01/1991 - "However, such an occlusive thrombus formation was significantly reduced by combined TXA2 synthase/prostaglandin endoperoxide receptor inhibition (5 mg/kg i.v. ridogrel; time to occlusion greater than 300 minutes, n = 7; incidence of occlusion within 300 minutes, one of seven experiments; p less than 0.05). "
08/01/1991 - "This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."
12/01/1992 - "Three hours after the formation of occlusive thrombus, animals were randomly assigned to receive one of the following: 1) t-PA (80 micrograms/kg + 8 micrograms.kg-1.min-1 i.v.) and saline; 2) t-PA and hirulog, a hirudin-based synthetic peptide and specific thrombin inhibitor (2 mg/kg + 2 mg.kg-1.hr-1 i.v.); 3) t-PA and ridogrel, a combined thromboxane A2 synthetase inhibitor and receptor antagonist (5 mg/kg + 2.5 mg.kg-1.hr-1 i.v.); or 4) t-PA, hirulog, and ridogrel. "
10/01/1990 - "30 min after thrombus formation, the animals received saline (controls, n = 10); SQ 29548 (0.4 mg/kg bolus + 0.4 mg/kg per h infusion), a TxA2/PGH2 receptor antagonist (n = 8); dazoxiben (5 mg/kg bolus + 5 mg/kg per h infusion), a TxA2 synthase inhibitor (n = 9); or R 68070 (5 mg/kg bolus + 5 mg/kg per h infusion), a drug that blocks TxA2/PGH2 receptors and inhibits TxA2 synthase (n = 8). "
08/01/1991 - "By contrast, occlusive thrombosis on deep vascular damage elicited by intraluminal stimulation (150-microA anodal constant current) in nonpreconstricted canine coronary arteries (time to occlusion, 237.1 +/- 13.9 minutes; n = 7; incidence of occlusion within 300 minutes, six of seven experiments) was not affected by platelet cyclooxygenase inhibition (5 mg/kg i.v. acetylsalicylic acid; n = 7), single TXA2 synthase inhibition (1.25 mg/kg i.v. ridogrel; n = 7), or single TXA2/prostaglandin endoperoxide receptor antagonism (10 mg/kg + 10 mg/kg/hr i.v. sulotroban for 300 minutes; n = 5). "
3. Crohn Disease (Crohn's Disease)
4. Hypertension (High Blood Pressure)
5. Necrosis

Related Drugs and Biologics

1. prostaglandin endoperoxide receptor
2. glucuronyl glucosamine glycan sulfate (Vessel)
3. Magnesium Sulfate (Sulfate, Magnesium)
4. Forskolin
5. A 127722
6. Thromboxane-A Synthase
7. Thromboxane A2 (A2, Thromboxane)
8. Heparin (Liquaemin)
9. Aspirin (Acetylsalicylic Acid)
10. Prostaglandin H2 (PGH(2))

Related Therapies and Procedures

1. Enema (Enemas)
2. Catheters
3. Ligation
4. Intraperitoneal Injections
5. Intra-Arterial Infusions